🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are escalating globally, with data suggesting in excess of 82 million new cases annually. Particularly high rates are seen in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the context of growing infection rates, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in the same week. This medication, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This establishes an equal footing with the typical regimen, which uses two antibiotics. The trial enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Doctors directly involved have voiced optimism. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.